Floatz logo

Montanide Isa 51

Lung Non-Small Cell Carcinoma

Roswell Park Cancer InstitutePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
89/ 100

Competitive context

1205 Active assets in the Lung Non-Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
d-0316
Betta Pharmaceuticals Co., Ltd.
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Montanide Isa 51 is also rated in:

Acute Myelogenous Leukemia (AML)Dormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →
melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →